ABEO - Abeona Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Abeona Therapeutics Inc.

1330 Avenue of the Americas
33rd Floor
New York, NY 10019
United States
646-813-4712
http://www.abeonatherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees88

Key Executives

NameTitlePayExercisedYear Born
Dr. João SiffertCEO, Head of R&D, Chief Medical Officer & Director862.45kN/A1963
Ms. Christine Berni-SilversteinAdvisor & Director434kN/A1983
Dr. Brian J. G. PereiraExec. ChairmanN/AN/A1959
Mr. Edward G. CarrChief Accounting Officer & Principal Financial OfficerN/AN/A1969
Mr. Jay BircherChief Technical OfficerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Corporate Governance

Abeona Therapeutics Inc.’s ISS Governance QualityScore as of December 5, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.